Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
Alto crecimiento
Los ingresos de la empresa han crecido de manera constante durante los últimos tres años, con un promedio interanual del 86.55%.
Creciendo
La empresa se encuentra en una fase de crecimiento. Sus ingresos anuales más recientes ascienden a 67.67M USD.
Infravalorada
El PE más reciente de la empresa es -4.90, en un rango percentil bajo de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 115.59M acciones, lo que supone una reducción del 10.01% con respecto al trimestre anterior.
En posesión de Catherine Wood
El inversor estrella Catherine Wood posee 13.84M acciones de este valor.